Xentuzumab

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation[1].

Product Specifications

CAS Number

[1417158-65-6]

Product Name Alternative

BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

UNSPSC

12352203

Target

IGF-1R

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/xentuzumab.html

Purity

99.71

Solubility

10 mM in DMSO

Smiles

[Xentuzumab]

Molecular Weight

(143.7 kDa)

References & Citations

[1]Weyer-Czernilofsky U, et al. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models. Mol Cancer Ther. 2020 Apr;19 (4) :1059-1069.